My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.14 +0.59 (+0.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

74 75 Next >

2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer ↗

December 29, 2023

During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.

Via Benzinga

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review ↗

December 29, 2023

The major indexes boast big annual gains with the Dow at record highs.

Via Investor's Business Daily

Topics Stocks

Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 ↗

December 28, 2023

2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.

Via Benzinga

Why Is Blood Purification Focused CytoSorbents Trading Lower Today? ↗

December 28, 2023

CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the...

Via Benzinga

Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry ↗

December 26, 2023

Via Benzinga

Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies ↗

December 26, 2023

Via Benzinga

Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry ↗

December 12, 2023

Via Benzinga

The Decline In Global Bond Yields Supports Stock Indices ↗

December 28, 2023

A decline in global bond yields is lending support to stocks on optimism that global central banks will start cutting interest rates next year.

Via Talk Markets

Topics Bonds

Why Is Cytokinetics (CYTK) Stock Up 70% Today? ↗

December 27, 2023

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Via InvestorPlace

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned ↗

December 27, 2023

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...

Via Benzinga

Investor Sentiment Improves; Dow Jumps Over 150 Points ↗

December 27, 2023

The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.

Via Benzinga

Topics Stocks

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

December 26, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher ↗

December 26, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The...

Via Benzinga

Topics Stocks

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

December 26, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Crude Oil Rises Over 3%; US Home Prices Increase In October ↗

December 26, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The...

Via Benzinga

Topics Stocks

US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs ↗

December 26, 2023

Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy.

Via Benzinga

AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies ↗

December 26, 2023

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio.

Via Benzinga

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

December 26, 2023

From AstraZeneca

Via Business Wire

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗

December 22, 2023

Friday, FDA approved AstraZeneca

Via Benzinga

These 3 Big Pharma Stocks Are Making Big Plays With AI ↗

December 22, 2023

Opportunity is in the air with AI, and these pharma giants are seizing the moment.

Via The Motley Fool

Topics Artificial Intelligence

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

December 21, 2023

From AstraZeneca

Via Business Wire

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry ↗

December 21, 2023

Which weight-loss stocks are good buys today?

Via The Motley Fool

Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗

December 20, 2023

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis...

Via Benzinga

COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs ↗

December 20, 2023

COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n

Via Benzinga

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗

December 19, 2023

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the

Via Benzinga

Why Is Compugen (CGEN) Stock Up 189% Today? ↗

December 19, 2023

Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

December 18, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest? ↗

December 18, 2023

2024 is going to be a sizzler in the biopharma sector.

Via The Motley Fool

Can Altimmune's weight-loss drug be a game-changer?

December 14, 2023

The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold

Via MarketBeat

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.